Pyrimethamine
Sold as Daraprim
Every registration of this product has been cancelled.
5-(4-Chlorophenyl)-6-ethylpyrimidine-2,4-diamine
Drag to rotate. Structure from PubChem CID 4993.
Background
Registration
- Applicants
- 2
- Registrations
- 2
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Glaxosmithkline South Africa (Pty) LimitedCancelled | Daraprim | Not stated | A0682 | Not determined | None |
| Wellcome pharmaceuticals *Cancelled | Daraprim | elixir | A0683 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Daraprim EACH TABLET CONTAINS PYRIMETHAMINE A 25 mg | Not listed | A0682 | Cancelled | Not determined | None |
| Daraprim elixir 5 ML PYRIMETHAMINE A 7,5 MG / 5 ML | Elixir | A0683 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Pyrimethamine
Consolidated Schedules 06 July 2026, line 7691
S3: Pyrimethamine
Consolidated Schedules 06 July 2026, line 4193
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.